De Novo: Unlocking Cardiac AI’s Billion Dollar Claims & Regulatory Clarity
If your cardiac AI has no predicate, the FDA De Novo Classification route is your path to market, and it’s the process that sets the…
Healthcare AI is entering clinical practice faster than the evidence framework can evaluate it. FDA has cleared over 1,451 AI-enabled medical devices. Digital health companies are publishing clinical data at unprecedented scale. And new regulatory pathways like the Predetermined Change Control Plan (PCCP) are creating adaptive frameworks for AI that evolves after deployment.
But what does the evidence actually prove? What’s the difference between a vendor’s internal validation study and a prospective randomized controlled trial? How do you evaluate whether an AI health platform has enough clinical evidence to trust with patient care?
This guide maps the clinical AI evidence landscape — from the evidence pyramid that classifies proof quality, to the regulatory pathways governing AI devices, to the companies building the strongest (and weakest) evidence bases in digital health.
If your cardiac AI has no predicate, the FDA De Novo Classification route is your path to market, and it’s the process that sets the…
What makes AI clinically reliable? Learn 5 key demands for AI in healthcare, from real patient data to continuous monitoring.
The FDA authorized 700+ AI medical devices by 2026. Understand TPL, real-world data, and transparency for your AI/ML submissions.
Ensure safe AI in healthcare. Learn how diverse data, strong governance, and continuous monitoring prevent bias and harm by 2026.
Can digital platforms cut employee BP 25%? See how Hello Heart and ACC's collaboration offers a data-driven path to better health and lower costs.
Protect patients and clinical integrity. Learn 5 key steps for safe AI in healthcare by 2026, from governance to real-world monitoring.
FDA Pathways and Peer-Review: The Bedrock of Clinical Reliability AI tools don’t just show up in the clinic. For them to be considered reliable, they…
Clinicians and investors both need to know which AI vendors actually improve medication adherence for hypertension. This gets right to the heart of what ‘value’…
The combination of artificial intelligence and behavioral science is changing cardiovascular care. The promise is for earlier detection, more precise diagnostics, sustained patient engagement, and…
Hypertension is a massive, persistent problem, and it’s a leading driver of heart disease and death. AI gets a lot of hype, but clinicians and…